ArticleEuropean radiology2026
Long-term clinical outcomes and short-term treatment efficacy evaluation based on longitudinal MR elastography in patients with chronic hepatitis C virus infection.
Article in European radiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Association Between Early and Long-Term Changes in Liver Stiffness in Patients with MASLD Undergoing Serial Magnetic Resonance Elastography.Diagnostics (Basel, Switzerland) · 2026Article
- Imaging-based fibrosis assessment and risk stratification in MASLD.Frontiers in medicine · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
Abstract
objectivesMagnetic resonance elastography (MRE) provides multiple quantitative biomarkers for assessing chronic liver disease. This study evaluated the prognostic value of MRE-based long-term liver stiffness (LS) changes in chronic hepatitis C virus (HCV) infection and explored short-term viscosity changes (loss modulus, LM) for monitoring responses to direct-acting antiviral treatment (DAA-Tx). MATERIALS AND
methodsOne hundred fifty-nine adults were included. We retrospectively analyzed 138 HCV participants with at least two 2D MREs, defining progression as an LS increase ΔLS ≥ 19% above baseline (LS
resultsAmong the 138 HCVs, 38 (27.5%) were progressors, with a ΔLS = 0.393 kPa/year; 11 developed LREs, showing a steeper rise of 0.614 kPa/year. LS
conclusionsTwo-dimensional MRE-assessed longitudinal change in LS can predict future clinical events in HCV patients, providing better risk stratification than LS alone. Multiparametric dual-frequency 3D MRE has promise for short-term changes in treatment effects. KEY POINTS: Question Accurately predicting clinical outcomes and monitoring direct-acting antiviral (DAA) treatment efficacy in HCV patients remains an unmet need. Findings Longitudinal LS changes predict future clinical events in HCV patients. Multiparametric dual-frequency 3D MRE detects short-term inflammatory and treatment-related changes, enhancing disease monitoring. Clinical relevance This study demonstrates longitudinal MRE as a reliable follow-up tool for chronic liver disease, enabling outcome prediction, risk stratification, and treatment monitoring, advancing personalized, non-invasive management for HCV patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.